Literature DB >> 27566286

The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013.

Alize J Ferrari1,2,3, Emily Stockings4, Jon-Paul Khoo2, Holly E Erskine1,2,3, Louisa Degenhardt3,4,5, Theo Vos3, Harvey A Whiteford1,2,3.   

Abstract

OBJECTIVES: We present the global burden of bipolar disorder based on findings from the Global Burden of Disease Study 2013 (GBD 2013).
METHODS: Data on the epidemiology of bipolar disorder were obtained from a systematic literature review and assembled using Bayesian meta-regression modelling to produce prevalence by country, age, sex and year. Years lived with disability (YLDs) were estimated by multiplying prevalence by disability weights quantifying the severity of the health loss associated with bipolar disorder. As there were no years of life lost (YLLs) attributed to bipolar disorder, YLDs equated to disability-adjusted life years (DALYs) as a measure of total burden.
RESULTS: There were 32.7 million cases of bipolar disorder globally in 1990 and 48.8 million in 2013; equivalent to a 49.1% increase in prevalent cases, all accounted for by population increase and ageing. Bipolar disorder accounted for 9.9 million DALYs in 2013, explaining 0.4% of total DALYs and 1.3% of total YLDs. There were 5.5 million DALYs recorded for female individuals and 4.4 million for male individuals. DALYs were evident from age 10 years, peaked in the 20s, and decreased thereafter. DALYs were relatively constant geographically.
CONCLUSIONS: Despite being relatively rare, bipolar disorder is a disabling illness due to its early onset, severity and chronicity. Population growth and aging are leading to an increase in the burden of bipolar disorder over time. It is important that resources be directed towards improving the coverage of evidence-based intervention strategies for bipolar disorder and establishing strategies to prevent new cases of the disorder.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; disability; epidemiology; global burden of disease; prevalence

Mesh:

Year:  2016        PMID: 27566286     DOI: 10.1111/bdi.12423

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  108 in total

1.  Positive and Negative Activation in the Mood Disorder Questionnaire: Associations With Psychopathology and Emotion Dysregulation in a Clinical Sample.

Authors:  Ryan W Carpenter; Kasey Stanton; Noah N Emery; Mark Zimmerman
Journal:  Assessment       Date:  2019-05-29

2.  The role of lifetime anxiety history in the course of bipolar spectrum disorders.

Authors:  Madison K Titone; Rachel D Freed; Jared K O'Garro-Moore; Andrew Gepty; Tommy H Ng; Jonathan P Stange; Lyn Y Abramson; Lauren B Alloy
Journal:  Psychiatry Res       Date:  2018-04-03       Impact factor: 3.222

Review 3.  Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.

Authors:  Jean-Michel Azorin; Nicolas Simon
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

4.  Magnetic seizure therapy is efficacious and well tolerated for treatment-resistant bipolar depression: an open-label clinical trial

Authors:  Victor M. Tang; Daniel M. Blumberger; Julia Dimitrova; Alanah Throop; Shawn M. McClintock; Daphne Voineskos; Jonathan Downar; Yuliya Knyahnytska; Benoit H. Mulsant; Paul B. Fitzgerald; Zafiris J. Daskalakis
Journal:  J Psychiatry Neurosci       Date:  2020-09-01       Impact factor: 6.186

5.  The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Stefanos Pittas; Xenophon Theodoridis; Anna-Bettina Haidich; Panteleimon-Vasilios Bozikas; Georgios Papazisis
Journal:  Psychopharmacology (Berl)       Date:  2021-02-27       Impact factor: 4.530

6.  Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Liping Hou; Scott R Clark; Sergi Papiol; Urs Heilbronner; Franziska Degenhardt; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Tatyana Shekhtman; Mazda Adli; Nirmala Akula; Kazufumi Akiyama; Raffaella Ardau; Bárbara Arias; Jean-Michel Aubry; Lena Backlund; Abesh Kumar Bhattacharjee; Frank Bellivier; Antonio Benabarre; Susanne Bengesser; Joanna M Biernacka; Armin Birner; Clara Brichant-Petitjean; Pablo Cervantes; Hsi-Chung Chen; Caterina Chillotti; Sven Cichon; Cristiana Cruceanu; Piotr M Czerski; Nina Dalkner; Alexandre Dayer; Maria Del Zompo; J Raymond DePaulo; Bruno Étain; Peter Falkai; Andreas J Forstner; Louise Frisen; Mark A Frye; Janice M Fullerton; Sébastien Gard; Julie S Garnham; Fernando S Goes; Maria Grigoroiu-Serbanescu; Paul Grof; Ryota Hashimoto; Joanna Hauser; Stefan Herms; Per Hoffmann; Andrea Hofmann; Stephane Jamain; Esther Jiménez; Jean-Pierre Kahn; Layla Kassem; Po-Hsiu Kuo; Tadafumi Kato; John Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Barbara König; Ichiro Kusumi; Gonzalo Laje; Mikael Landén; Catharina Lavebratt; Marion Leboyer; Susan G Leckband; Alfonso Tortorella; Mirko Manchia; Lina Martinsson; Michael J McCarthy; Susan McElroy; Francesc Colom; Marina Mitjans; Francis M Mondimore; Palmiero Monteleone; Caroline M Nievergelt; Markus M Nöthen; Tomas Novák; Claire O'Donovan; Norio Ozaki; Urban Ösby; Andrea Pfennig; James B Potash; Andreas Reif; Eva Reininghaus; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; Peter R Schofield; Barbara W Schweizer; Giovanni Severino; Paul D Shilling; Katzutaka Shimoda; Christian Simhandl; Claire M Slaney; Alessio Squassina; Thomas Stamm; Pavla Stopkova; Mario Maj; Gustavo Turecki; Eduard Vieta; Julia Volkert; Stephanie Witt; Adam Wright; Peter P Zandi; Philip B Mitchell; Michael Bauer; Martin Alda; Marcella Rietschel; Francis J McMahon; Thomas G Schulze; Bernhard T Baune
Journal:  JAMA Psychiatry       Date:  2018-01-01       Impact factor: 21.596

Review 7.  Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Bernhard T Baune
Journal:  EPMA J       Date:  2017-09-05       Impact factor: 6.543

8.  Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.

Authors:  Bernardo Sampaio-Junior; Gabriel Tortella; Lucas Borrione; Adriano H Moffa; Rodrigo Machado-Vieira; Eric Cretaz; Adriano Fernandes da Silva; Renério Fraguas; Luana V Aparício; Izio Klein; Beny Lafer; Stephan Goerigk; Isabela Martins Benseñor; Paulo Andrade Lotufo; Wagner F Gattaz; André Russowsky Brunoni
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

Review 9.  [Genetics of bipolar disorder].

Authors:  M Budde; A J Forstner; K Adorjan; S K Schaupp; M M Nöthen; T G Schulze
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

10.  Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial.

Authors:  Diego Freitas Tavares; Paulo Suen; Carla Garcia Rodrigues Dos Santos; Doris Hupfeld Moreno; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; André R Brunoni; Ricardo Alberto Moreno
Journal:  Neuropsychopharmacology       Date:  2021-06-30       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.